V. Devauchelle-Pensec's research while affiliated with Centre Hospitalier Universitaire de Nancy and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (44)
Background
Sjögren’s Syndrome (SjS) is a complex autoimmune disease predominantly affecting the salivary and lacrimal glands, leading to hallmark symptoms such as dry eyes and mouth. Its distinctive clinical manifestations, coupled with symptom overlap with other disorders, make its diagnosis challenging. Traditional diagnostic criteria, as outline...
Background
Pulmonary manifestations of primary Sjögren disease (SD) have been described in 9-20% of patients, are highly heterogeneous and have also been linked to increased mortality.
Objectives
To characterize pulmonary manifestations in a large cohort of patients with SD.
Methods
We collected data on pulmonary manifestations in patients with S...
Background
Neurological manifestations can occur in up to half of patients with Sjögren disease (SjD) and the peripheral nervous system (PNS) is the most commonly involved (5-21%).
Objectives
To analyze the frequency and phenotypic expression of PNS involvement at the time of SjD diagnosis
Methods
The Big Data Project Consortium is an internation...
Background
Sjögren disease (SjD) is the autoimmune disease with the highest risk of lymphoma. The most common histology is marginal zone (MZ) lymphoma particularly the mucosa-associated lymphoid tissue (MALT) lymphoma. There is a continuum between autoimmunity and lymphoma, and disease activity is a major risk factor for lymphoma development. Manag...
Background
Sjögren’s disease (SjD) is a heterogenous autoimmune disease, with a wide range of symptoms, from dryness, fatigue, pain, to systemic manifestations, and an increased risk of lymphoma. Recently, three clusters of patients with SjD have been described based on unsupervised clustering analysis according to symptoms, clinical signs and biol...
Background
Central nervous system (CNS) involvement is one of the numerous extra-glandular manifestations of primary Sjögren disease (SjD) and it has been described in 8-70% of patients at various stages of the disease.
Objectives
To characterize how CNS involvement presents at the diagnosis of SjD.
Methods
The Big Data Sjögren Consortium is an i...
Background
The SEMAPHORE trial[1] was a randomized controlled prospective study to assess the safety and efficacy (success defined by PMR-AS≤10 and GC≤5mg or GC decrease ≥10mg/day) of intra venous (i.v.) tocilizumab (TCZ) in glucocorticoids (GC)-dependent polymyalgia rheumatica (PMR). Tocilizumab was shown to reduce GC while improving clinical and...
Background
The epidemiological and immunopathogenic association between Sjögren disease (SD) and non-Hodgkin’s lymphoma (NHL) is well-established. However, the epidemiological data on this complication mostly relies on data from tertiary centers, introducing selection bias and limiting comprehensive case capture.
Objectives
This study aimed to eva...
Background
Spondyloarthritis (SpA) regularly affects women of childbearing age [1]. A higher obstetric morbidity in women with SpA is suggested in the literature in several countries, but no comparison between SpA patients and women in the general population is available for France. Furthermore, there is very few data on fertility in SpA patients....
Background
Rheumatoid arthritis (RA) regularly affects women of childbearing age¹. A higher obstetric morbidity in women with RA is suggested in the literature in several countries, but no comparison between patients with RA and women in the general population is available for France.
Objectives
The aim of the study was to compare adverse fetal, m...
Background:
What baseline predictors would be involved in mortality in people with primary Sjögren syndrome (SjS) remains uncertain. This study aimed to investigate the baseline characteristics collected at the time of diagnosis of SjS associated with mortality and to identify mortality risk factors for all-cause death and deaths related to system...
Background
Within the group of inflammatory myopathies, Inclusion-Body Myositis (IBM) is a distinct pathology with clinical and histological features very different from other entities. In the literature, an association between primary Sjögren’s syndrome (pSS) and IBM has been previously reported.
Objectives
The aim of our study was to compare the...
Background
Primary Sjögren’s syndrome (pSS) is a B-cell driven systemic auto-immune disease associated with the highest risk of lymphoma among systemic auto-immune diseases. In the prospective ASSESS cohort (395 patients enrolled, with a 10-year follow-up), transcriptomic analysis recently showed the association between baseline peripheral blood ov...
Background
The diagnosis of primary Sjögren Disease (SjD) is currently based on a combination of clinical, histological and biological findings [1]. Current thinking supports anti-Ro60 antibodies as the most specific serum marker, while the impact of anti-Ro52 remains unclear [2].
Objectives
The aim of this study was to characterize the clinical,...
Background
Primary Sjögren Syndrome (pSS) patients have an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management of low-grade NHL. Two strategies can be proposed; either a ‘‘wait and see’’ strategy or an active therapeutic strategy.
Objectives
To describe characteristics of NHL in pSS, therapeutic strate...
Background
Polymyalgia rheumatica (PMR) is an inflammatory disease. But it’s pathophysiology and the impact of the treatments on immune cells are poorly known.
Objectives
Our objectives were to describe the immune cells of patients with PMR dependent from glucocorticoids and to analyze their evolution under tocilizumab.
Methods
The SEMAPHORE tria...
Background
Salivary gland ultrasonography (SGUS) is commonly used in primary Sjögren Disease (pSD) as a diagnostic tool [1]. It could also be used to monitor disease activity, but severity of SGUS parenchymal abnormalities in relation to disease duration is not well characterized.
Objectives
To assess transversally the severity of ultrasound saliv...
Background
The main treatment of polymyalgia rheumatica (PMR) are glucocorticoids (GC) with a 6-month decrease target, but 45% of patients have an unfavourable evolution with relapses or glucocorticoids dependence. Poor prognostic factors in PMR are understudied and controversial.
Objectives
The aim of this work was to identify predictive factors...
Background
The main treatment of polymyalgia rheumatica (PMR) is based on corticosteroid, but sparing agents are a major unmet need and many new treatments are evaluated to avoid corticosteroid side effects in PMR. To monitor the disease, one disease activity score has been developed specifically for polymyalgia rheumatica (PMR), the PMR-AS (activi...
Resumen
La polimialgia reumática (PR) y la arteritis de células gigantes (ACG) pueden presentarse asociadas o independientemente una de la otra en pacientes mayores de 50 años. La PR se manifiesta esencialmente por dolor inflamatorio en las cinturas. La ACG puede presentarse como una enfermedad arterítica craneal, con cefalea como signo dominante,...
Background
Spondyloarthritis (SpA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age ¹ . However, there is limited knowledge about the impact of the disease and its treatment on pregnancy.
Objectives
The aim of the study was to determine the factors associated with adverse pregnancy outcome in...
Background
The prevalence of salivary glands ultrasound (SGUS) abnormalities in Sjögren’s syndrom (SS) is well described ⁽²⁾ . However, the prevalence is still unknown in rheumatic inflammatory conditions such as rheumatoid arthritis (RA).
Objectives
The main objective of this study was to describe the prevalence of SGUS parenchymal structural abn...
Background
Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age ¹ . However, there is limited knowledge about the impact of the disease and its treatment on pregnancy.
Objectives
The aim of the study was to determine the factors associated with adverse pregnancy outcome i...
Background
Primary Sjögren’s syndrome (pSS) is a rare systemic autoimmune disease with no specific treatment at present. To better assess patient symptoms, we have developed a web application (WebApp) to collect patient symptom intensity on a regular basis.
Objectives
To measure the daily variability of symptoms using the WebApp. We also evaluated...
Background
The low prevalence of systemic autoimmune diseases and the diversity of their clinical manifestations make complex to conduct randomised clinical trials to assess the potential efficacy of targeted treatments.
Objectives
To assess the tolerance and efficacy of targeted therapies prescribed off-label in refractory autoimmune diseases.
M...
Background
Today, there are still no DMARDs licensed for primary Sjögren Syndrome (pSS) patients. Among the explanations, are the limitations of current outcome measures used as primary endpoints: e.g; high placebo response rate, evaluation of either symptoms or systemic activity, and important features not being assessed. The NECESSITY consortium...
Background
Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age ¹ . However, there is limited knowledge about the impact of the disease and its treatment on fertility.
Objectives
The aim of the study was to determine factors associated with time-to-conception in women wit...
Background
Treatment of children with juvenile idiopathic arthritis (JIA) is a major challenge in paediatric rheumatology. The presence of synovitis, which is difficult to detect in children, is associated with structural damage. Musculoskeletal ultrasonography (MSUS) can be used in JIA patients to reveal subclinical synovitis.
Objectives
Our aim...
Background
The COVID-19 pandemic has raised concerns about its psychological effects. Sleep disturbances, anxiety and/or depressive symptoms, post-traumatic stress symptoms have been reported in general population. Patients with chronic rheumatism, systemic autoimmune disease or auto-inflammatory disease, due to immunosuppression, are at risk of se...
Introduction
Evaluer la tolérance et l’efficacité des thérapies ciblées prescrites hors AMM au cours des maladies auto-immunes systémiques réfractaires.
Matériels et méthodes
Le registre TATA (TArgeted Therapy in Autoimmune Diseases) est un suivi de cohorte prospectif observationnel national, indépendant. Les critères d’inclusion dans le registre...
Background
In 2017, TOCILIZUMAB (TCZ) obtained marketing authorization for treatment of giant cell arteritis (GCA); however, this doesn’t extend to polymyalgia rheumatica (PMR) therapy. Based on efficacy data for TCZ in GCA, TCZ is sometimes used as a glucocorticoid (GC) sparing agent when PMR is GC dependent or when a rapid steroid withdraw is nee...
Background
Sjögren’s syndrome (SS) is a chronic, systemic autoimmune disorder characterised by oral and ocular dryness related to lymphocytic infiltration of exocrine glands. 1–3 Extra-glandular manifestations may include fatigue, musculoskeletal pain and glomerulonephritis. 1,3 SS can present as primary SS (pSS) or as SS associated with another au...
Background
polymyalgia rheumatica (PMR) is a chronic inflammatory disorder affecting elderly people. Glucocorticoids (GC) are the mainstay of therapy for PMR. Despite this treatment, the disease may relapse or GC dosage cannot be tapered. Methotrexate (MTX) may be helpful in these cases. Blockade of IL-6 has an effective steroid-sparing effect in p...
Objective
To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS.
Methods
We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an i...
Introduction
Les atteintes cutanées sont habituelles au cours du syndrome de Gougerot-Sjögren primitif (SSp), mais leur prévalence et leurs caractéristiques sont difficiles à établir précisément en raison du nombre limité de patients étudiés dans la plupart des cohortes, de la variabilité des signes fonctionnels et cliniques évalués dans chaque coh...
Resumen
El síndrome de Sjögren primario es una enfermedad sistémica autoinmunitaria que se caracteriza principalmente por una lesión inflamatoria de las glándulas salivales y lacrimales que provoca un síndrome de sequedad ocular y bucal, pero que también puede afectar a múltiples órganos. A veces puede estar asociado con otra enfermedad sistémica;...
Background
Cutaneous involvement is common during primary Sjogren’s Syndrome (pSS) but prevalence and characteristics are difficult to establish precisely because of the limited number of patients studied in most cohorts, the variability of the disorders evaluated in each cohort, the rarity of some of them, and the heterogeneity of evaluations from...
Background
For rheumatologists monitoring patients with various diseases and dealing with multiple scores with different maximum values (9 for RA-DAS, 6.4 for AS-DAS and 60 for PMR-AS) and values thresholds to characterize the different levels of disease activity (low, intermediate and high) can be a tedious task. The same problematic could arise i...
Introduction
L’IL-6 joue un rôle important dans la physiopathologie du syndrome de Sjögren primaire (SJp), notamment via l’activation des lymphocytes B et la polarisation des lymphocytes T. Nous avons réalisé un essai randomisé en double aveugle Tocilizumab versus placebo (ETAP, Efficacité et Tolérance du RoActemra au cours du syndrome de Sjögren P...
Introduction
Le nombre d’articles publiés chaque année augmente de manière rapide et constante. Réaliser manuellement une revue de la littérature systématisée devient une tâche de plus en plus ardue, en particulier si le sujet est complexe.
Matériel et méthodes
Nous avons comparé les résultats d’une recherche classique et d’une recherche similaire...
Background Heterogeneity is a major obstacle to developing effective treatments for patients with primary Sjögren's syndrome. We aimed to develop a robust method for stratification, exploiting heterogeneity in patient-reported symptoms, and to relate these differences to pathobiology and therapeutic response. Methods We did hierarchical cluster ana...
Introduction
Il y a peu de données de vie réelle en France sur la prise en charge des patients atteints d’artérite à cellules géantes (Horton, ACG). L’objectif de l’étude ARTEMIS était de décrire les caractéristiques et la prise en charge diagnostique et thérapeutique des patients atteints d’ACG en France en vie réelle.
Patients et méthodes
Cette...
Citations
... Cryoglobulinemic vasculitis typically affects the skin, peripheral nerves, joints, and kidneys. Cryoglobulinemic vasculitis is rarely idiopathic and often occurs in association with various chronic inflammatory diseases and chronic infections [9][10][11][12][13][14]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/290240636964867-1446210168278_Q64/Ildiko-Horvath-4.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/939743965618178-1601063829448_Q64/Astrid-Rasmussen.jpg)
... For these reasons, RF has been included in the biological domain of the new composite scores: Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) and Sjögren's Tool for Assessing Response (STAR), both of which aim to measure activity of the disease. 12 Last, even if nonspecific ANA and RF positivity do not define seropositive SS, it is probable that a patient with nonspecific ANA, RF, hypergammaglobulinemia, and sicca symptoms has SS. Interestingly, although the majority of industrial clinical trials mandate the inclusion of patients with anti-SSA antibodies, some of them also admit seronegative individuals with RF or a high titer of ANA so long as they meet SS criteria, confirmed through a positive minor salivary gland biopsy (MSGB). ...
... Patients with active disease have higher risk of preterm delivery and small-for-gestational-age infants. Women with spondyloarthritis have also higher risk of elective and emergency Cesarean delivery and higher risk for preeclampsia [65][66][67][68][69]. During labor and delivery, neuraxial anesthesia should be preferred and general anesthesia should be avoided if possible [70]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272737524514842-1442037101783_Q64/Anna-Molto.jpg)
... A total of 7/62 (11.3%) studies reported on the incidence of primary Sjögren's within a sample cohort taken from the general population (Supplementary Data S9) [21][22][23][24][25][26][27]. Where reported, overall sample sizes ranged from 113,306 to *4.5 million people. ...
... Furthermore, when SS combined with COVID-19 was a multiple cause-of-death, 73 deaths occurred in 2020 alone, 9% of the total SS-related deaths in the last 22 years. This may be related to the potential abnormal immune response and frequent use of immunosuppressants in patients with SS, causing a high hospitalization rate and poor prognosis [36], including respiratory failure and esophageal lymphocytosis, leading to patient death. Studies have shown increased risks of hospitalization and death, particularly in patients treated with corticosteroids [37]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272675964715036-1442022425460_Q64/Roberta-Priori.jpg)
... To date, the vast majority of drugs have failed to demonstrate clinical efficacy based on the outcomes of corresponding randomized placebo-controlled trials; therefore, no drugs have been officially licensed for the treatment of SjS [106]. However, when stratifying patients based on symptoms, the effects of drugs can be positive for specific subgroups of patients [107], and the heterogeneity of SjS pathogenesis is attributable to these findings and highlights the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1080591315415045-1634644454397_Q64/Dennis-Lendrem.jpg)
